Hasil Pencarian  ::  Simpan CSV :: Kembali

"Ischialgia merupakan gejala dari penyakit yang menyerang saraf Ischiadicus dan banyak dijumpai di poliklinik Saraf RS Duren Sawit. Penyakit ini tidaklah fatal akan tetapi cukup memberikan penderitaan bagi yang menderitanya. Rasa sakit di bokong yang menjalar ke tungkai merupakan ciri khas penyakit ini,dan sering menimbulkan gangguan untuk aktivitas sehari-hari. Penatalaksanaan penyakit ini,umumnya hanya berupa pengobatan konservatif dengan pemberian anti inflamasi, sambil menunggu regerasi saraf yang teriritasi. Kerugian ekonomis yang ditimbulkan oleh penyakit ini sangatlah besar, belum lagi jika dilihat dari tidak dapatnya penderita bekerja akibat sakitnya. Apalagi jika dinilai penderitaan yang diakibatkan penyakit ini sangat mengganggu dan cukup lama. Untuk itu diperlukan terobosan baru bagi penatalaksanaan penyakit ini. Operasi memang dapat menyembuhkan penyakit ini akan tetapi membutuhkan biaya yang tidak sedikit, belum lagi resiko komplikasi operasi dan kemungkinan relaps. Blok Saraf adalah upaya lain yang selain murah, mudah dilaksanakan dan secara cepat dapat menghilangkan nyeri yang diakibatkan penyakit ini. Dari hasil penelitian yang dilakukan di Poliklinik Saraf RS Duren Sawit ini dimana penderita diberi tindakan blok saraf, selain diberi obat konservatif dibandingkan dengan pemberian obat saja ternyata tindakan blok saraf terbukti lebih cost effective untuk menyembuhkan penyakit ini. Dengan keberhasilan tindakan blok saraf untuk kasus Ischialgia,kedepan, dapat juga untuk dilakukan percobaan untuk kasus nyeri bagi penyakit lain.

---

Cost Effectiveness Analysis Symptomatic Treatment of Ischialgia Patient in Policlinic Neurology Duren Sawit Hospital, 2004Ischialgia, symptom of disease that affect Ishciadicus nerves is found in many of ,. the patient in Policlinic Neurology Duren Sawit Hospital. This disease is not categorized as a deadly one although it can give severe pain to the patient. The throbbing sensation start from, the buttock goes down to the leg is the specific character of this disease which often impair patient daily. Medical treatment is generally done by giving an anti inflammatory drug while waiting for the irritated nerves to regenerate themselves.

Economic loss caused by this diseases is substantial as the patients are usually unable to do their activity due to severe pain for a quite long period of time. The new breakthrough medical treatment for these diseases is done through surgery, though the expense will not be small and the risk of complication as well as disease relapse makes this option not being preferred. Blocking the peripheral nerve is another option that has been considered as easier, cheaper and quicker in eliminating the back pain sensation.

The result of this experimental study which compare the treatment of Nerve Block plus drugs with drugs treatment only have proven that The Nerve Block treatment is more cost effective than conventional treatment. With this successful finding, it is recommended to perform Nerve Blocking treatment to other cases of ischialgia."

"Infeksi kaki diabetik (IKD) menjadi masalah utama secara global untuk pasien dan sistem pelayanan kesehatan. Selain mempertimbangkan efektivitas antibiotik, beban biaya medis pengobatan juga menjadi perhatian utama dalam penelitian ini. Tujuan penelitian ini adalah analisis efektivitas-biaya antara ampisilin/sulbaktam dan non-ampisilin/sulbaktam pada pasien IKD rawat inap. Desain penelitian ini kohort retrospektif dengan menggunakan data rekam medis dan data biaya pengobatan di RSUPN Dr. Cipto Mangunkusumo. Perbaikan klinis infeksi kaki dinilai pada periode 5-7 hari dan dihitung total biaya medis langsung. Total 135 pasien IKD rawat inap teriklusi terdiri dari 93 pasien kelompok ampisilin/sulbaktam dan 42 pasien kelompok non-ampisilin/sulbaktam. Tidak ada perbedaan signifikan dalam efektivitas perbaikan klinis IKD pada kedua kelompok (55,9% vs 64,3%; p = 0,361). Pada analisis bivariat, derajat infeksi luka ringan 1,63 kali lebih berpeluang mencapai perbaikan klinis infeksi dibandingkan dengan pasien derajat sedang-berat (p = 0,026). Tidak ada perbedaan signifikan pada total biaya medis langsung antara ampisilin/sulbaktam dengan non-ampisilin/sulbaktam (Rp30.645.710 vs Rp32.980.126; p = 0,601). Pada perhitungan ACER dan model decision-tree, kelompok non-ampisilin/sulbaktam lebih cost-effective dibandingkan ampisilin/sulbaktam. Pada perhitungan ICER non-ampisilin/sulbaktam, untuk penambahan 1% perbaikan klinis IKD, dibutuhkan biaya tambahan sebesar Rp 277.907.

---

Diabetic foot infections (DFI) is a major problem globally and health system services. In addition to considering effectiveness of antibiotics, the burden of medical treatment costs is also a major concern in this study. This study aimed to analyze cost-effectiveness between ampicillin/sulbactam and non-ampicillin/sulbactam in hospitalized DFI patients. The design of this study was a retrospective cohort using medical record data and medical cost data at Dr. Cipto Mangunkusumo National Referral Hospital. Assessment of clinical improvement of foot infections in 5-7 days and calculated total direct medical costs. A total of 135 inpatients with DFI, consisting of 93 patients in the ampicillin/sulbactam group and 42 patients in the non-ampicillin/sulbactam group. There was no significant difference in the effectiveness of clinical improvement between two groups (55.9% vs. 64.3%; p = 0.361). In bivariate analysis, mild infection had a 1.63 times probability of clinical improvement compared to moderate-severe infection (p = 0.026). There was no significant difference in total direct medical costs (IDR 30,645,710 vs IDR 32,980,126; p = 0.601). In ACER and decision-tree models, non-ampicillin/sulbactam group was more cost-effective. In ICER of non-ampicillin/sulbactam, for an additional 1% of clinical improvement in DFI, an additional fee of IDR 277,907 is required."

"ABSTRAKTeknik anesthesia regional blok subarachnoid (RA BSA) adalah yang palingbanyak dilakukan setelah teknik anesthesia umum inhalasi pipa endotrakea (GAPET) di RSUP Sanglah. Teknik anesthesia regional blok subarachnoid dapatmenggantikan teknik anesthesia umum pipa endotrakea pada pasien minilaparatomi (appendisectomy dan laparatomi kehamilan ektopik). Belum pernahdilakukan studi tentang cost effectiveness analysis (CEA) pada teknik anesthesiaregional blok subarachnoid di RSUP Sanglah. Cost diambil dari catatan medispenggunaan obat di ruang operasi dan ruang pemulihan. Outcome (efektifitas)dilihat dari kejadian efek samping pasca operasi (nyeri akut pasca operasi, mualmuntah pasca operasi / PONV dan menggigil (shivering) . Hasil penelitianmenunjukkan bahwa teknik anesthesia regional blok subarachnoid lebih costeffective daripada teknik anesthesia umum pipa endotrakea pada pasien minilaparatomi (appendisectomi dan laparatomi kehamilan ektopik) di RSUP SanglahBali.

---

ABSTRACTRegional anesthesia blok subarachnoid is the most common anesthesia techniqueafter general anesthesia endotracheal tube at RSUP Sanglah. Regional anesthesiablok subarachnoid can replaced the general anesthesia endotracheal tube forminilaparatomy (appendisectomy & laparotomy ectopic pregnancy) patient. Noneof report on cost effectiveness analysis for regional anesthesia blok subarachnoidat RSUP Sanglah. Cost were calculated from anesthesia record paper at theoperating room and recovery room. Outcome were taken from side effect afteroperation (acute pain, post operative nausea vomiting and shivering). The result,anesthesia regional blok subarachnoid were more cost effective than generalanesthesia endotracheal tube for mini laparotomy (appendisectomy andlaparotomy ectopic pregnancy) at RSUP Sanglah Bali."

"Contents :- Preface - Chapter 1: Building and managing an effective indigenous workforce - Chapter 2: Evaluating a global sales training program - Chapter 3: A learning intervention for work engagement - Chapter 4: Success through managers program ROI study - Chapter 5: Measuring the impact of conflict management skills training - Chapter 6: Technical training case study - Chapter 7: The ROI in using colleagues as coaches - Chapter 8: Lean concepts in healthcare: a return on investment study - Chapter 9: Store operations development workshop - Chapter 10: Measuring the ROI in business performance management - Chapter 11: Developing the ROI of an online English-as-a-second-language program - Chapter 12: Consultative sales program in a telecommunications company - Chapter 13: Determining impact and ROI for knowledge management - Chapter 14: Winning every walk-in - Chapter 15: Measuring ROI in a sales force coaching program - About the editors - About the ROI Institute "

"ABSTRAKDiabetes mellitus tipe 2 DMT2 adalah suatu kondisi ketika sel tubuh resisten terhadap insulin yang dihasilkan oleh sel ? pankreas. World Health Organization WHO memperkirakan prevalensi penderita DMT2 akan terus meningkat terutama di negara-negara berkembang termasuk Indonesia. Pengobatan diabetes jangka panjang, pola peresepan yang beragam dan perbedaan harga insulin dibandingkan sulfonilurea dan biaguanid menyebabkan perbedaan biaya yang dikeluarkan untuk terapi. Penelitian merupakan analitik deskriptif dengan desain cross sectional.Penelitian dilakukan untuk mengetahui efektivitas pengobatan dan efisiensi biaya antidiabetes pada pasien DMT2 rawat jalan di RSK Dr. Sitanala Tangerang pada periode April 2015 - Juni 2015 yang mengkomsumsi obat yang sama selama 4 bulan terakhir. Subjek penelitian dibagi menjadi tiga kelompok yaitu yang menggunakan insulin n=29 , yang menggunakan obat sulfonilurea n=29 dan yang menggunakan kombinasi sulfonilura-biguanid n=39 .Efektivitas pengobatan dilihat dari nilai HbA1c pasien dan analisis antidiabetes dari segi efektivitas pengobatan dan biaya dilakukan dengan menggunakan Cost Effectiveness Analysis CEA . Hasil penelitian menunjukkan bahwa pasien DMT2 berjenis kelamin perempuan lebih banyak dibandingkan pasien laki-laki yaitu 68 orang 65,96 dengan rata-rata usia pasien DMT2 yaitu 50-59 tahun. Efektivitas tertinggi dihasilkan oleh kombinasi sulfonilurea-biguanid yaitu 7,48 1,89. Nilai ACER Average cost effectiveness ratio kelompok insulin adalah Rp. 40.866, kelompok sulfonilurea adalah Rp. 1.369 dan kelompok kombinasi sulfonilurea-biguanid adalah Rp. 2.621. Nilai ICER incremental cost effectiveness ratio untuk terapi sulfonilurea-biguanid terhadap terapi sulfonilurea adalah Rp. 16.194. Berdasarkan analisis yang dilakukan, terapi kombinasi sulfonilurea-biguanid lebih cost effective dibandingkan terapi insulin ataupun terapi sulfonilurea tunggal.

---

ABSTRACTType 2 diabetes mellitus T2DM is a condition when the body cells are resistant to insulin produced by the pancreas cells. World Health Organization WHO estimates that the prevalence of type 2 diabetes will continue to increase, especially in developing countries, including Indonesia. Long term diabetes treatment, prescribing pattern varied and the price difference compared to sulfonylurea insulin and biaguanid cause differences in costs incurred for treatment. The research is descriptive analytic with cross sectional design.The study was conducted to examine the effectiveness and cost efficiency antidiabetic treatment in patients with type 2 diabetes outpatient Dr. Sitanala Leprosy Hospital in Tangerang in the period April 2015 June 2015 were consuming the same drug during the last 4 months. Subjects were divided into three groups who use insulin n 29 , which uses a sulfonylurea drug n 29 and those using sulfonilura biguanide combination n 39 .The effectiveness of treatment views of HbA1c values of patients and analysis of antidiabetic terms of the effectiveness of treatment and the cost is done by using the Cost Effectiveness Analysis CEA . Results showed that patients with type 2 diabetes were female more than male patients ie 68 65.96 with an average age of patients with type 2 diabetes that is 50 59 years. The highest effectiveness generated by the combination of sulfonylurea biguanide is 7.48 1.89. Value ACER Average cost effectiveness ratio insulin group is Rp. 40 866, sulfonylurea group is Rp. 1369 and the combination of sulfonylurea biguanide group is Rp. 2,621. Value ICER incremental cost effectiveness ratio for the treatment of sulfonylurea biguanide to sulfonylurea therapy is Rp. 16 194. Based on the analysis performed, sulfonylurea biguanide combination therapy is more cost effective than sulfonylurea insulin therapy or single therapy."

"Rumah Sakit Karya Bhakti Pratiwi telah menggunakan seftriakson baik generik maupun bermerek dagang sebagai lini pertama terapi demam tifoid sejak tahun 2012 berdasarkan pola kepekaan antibiotik RS tersebut. Perbedaan harga yang signifikan antara kedua jenis seftriakson mendorong berlangsungnya penelitian ini. Analisis efektivitas-biaya AEB dilakukan untuk mengukur dan membandingkan efektivitas serta biaya antara kedua jenis pengobatan sehingga dapat menentukan jenis pengobatan yang lebih cost-effective. Penelitian berupa penelitian analitik cross-sectional secara retrospektif yaitu data penggunaan seftriakson sebagai terapi untuk pasien anak demam tifoid pada tahun 2016 dengan metode total sampling. Data yang digunakan adalah data sekunder, yaitu data peresepan dan data keuangan dari sistem informasi manajemen rumah sakit. Sampel yang dilibatkan dalam analisis adalah sebanyak 63 pasien, yaitu 43 pasien kelompok seftriakson generik dan 20 pasien kelompok seftriakson bermerek dagang. Efektivitas pengobatan diukur berdasarkan lama hari rawat. Biaya didapatkan dari median total biaya pengobatan, meliputi biaya obat, biaya laboratorium, biaya alat kesehatan, biaya pelayanan dan biaya rawat inap. Berdasarkan hasil penelitian, efektivitas seftriakson generik setara dengan seftriakson bermerek dagang dengan median lama hari rawat sebesar 4 hari. Hasil penelitian yang dinyatakan dalam rasio efektifitas biaya REB menunjukkan bahwa seftriakson generik REB: Rp.575.937,25/hari lebih cost-effective dibandingkan seftriakson bermerek dagang REB: Rp.888.601,75/hari.

---

Karya Bhakti Pratiwi Hospital has been using generic ceftriaxone and branded ceftriaxone for typhoid fever first line therapy in pediatric patients since 2012. The significant difference in the cost of both ceftriaxone type encouraged researcher to perform Cost effectiveness analysis CEA . CEA was performed to measure and compare the effectivity and the cost of the two kinds of therapy so the more cost effective therapy can be determined. The study design was a cross sectional ndash analytical study. Data were collected retrospectively with total sampling method. The data consisted of prescribing data and administrative financial data. The number of samples were 63 patients, consisted of 43 patients with generics ceftriaxone and 20 patients with branded ceftriaxone. The effectiveness of the therapy were measured as length of stay of the patients. The total cost of therapy was the median of summed calculation of cost of drugs, cost of laborartory examination, cost of medical devices usage, cost of physician service, and cost of hospitalization. The results of this study shows that the effectiveness of both generics and branded ceftriaxone was 4 days of stay. The analysis result as cost effectiveness ratio showed that generics ceftriaxone CER Rp.575,937.25 day is more cost effective than branded ceftriaxone CER Rp.888,601.75 day."

"ABSTRAKTransfusi darah dibutuhkan dalam meningkatkan kualitas hidup pasien thalassemia mayor, namun dapat menyebabkan kelebihan zat besi, sehingga diperlukan terapi kelasi besi, seperti deferipron dan deferasirox. Tujuan penelitian ini adalah menganalisis obat yang lebih cost-effective dengan metode Analisis Efektivitas-Biaya AEB karena masing-masing obat memiliki perbedaan efektivitas dan biaya obat yang signifikan. Data diambil secara retrospektif dan pengambilan sampel dilakukan secara total sampling berdasarkan catatan rekam medik dan sistem informasi rumah sakit. Pasien yang diikutsertakan merupakan pasien anak-anak pengguna deferipron n=33 dan deferasirox n=27 yang rutin melakukan transfusi darah pada tahun 2016. Efektivitas pengobatan diukur berdasarkan perubahan kadar serum ferritin. Biaya didapatkan dari median total biaya pengobatan, meliputi biaya obat, alat kesehatan, tindakan, administrasi dan jasa dokter, laboratorium serta kantong darah. Berdasarkan hasil penelitian, deferasirox 1.164 ng/mL lebih efektif dari deferipron 692 ng/mL dan median total biaya pengobatan deferasirox lebih mahal. Hasil akhir menunjukkan bahwa rasio efektivitas-biaya deferasirox Rp 65.816,68 lebih rendah dari deferipron Rp 74.956,60 , namun keduanya tidak ada yang mendominasi sehingga tidak dapat ditentukan terapi yang lebih cost-effective. Bila pengobatan deferipron dipilih, perlu dikeluarkan biaya tambahan sebesar Rp 52.416,64 untuk peningkatan satu unit efektivitas dan pengambil kebijakan di pelayanan kesehatan harus mempertimbangkan apakah biaya lebih tersebut sebanding dengan peningkatan efektivitasnya.

---

ABSTRAKBlood transfusions are needed in improving the quality of life of major thalassemia patients, but it can lead to excess iron, so it requires iron chelation therapy, such as deferiprone and deferasirox. This study is aimed to analyse whether deferipron or deferasirox is more cost effective with Cost Effectiveness Analysis CEA method because each drug has a significant difference in effectiveness and drug costs. Data were taken retrospectively and sampling was done using total sampling based on medical records and hospital information systems. Patients which included are pediatric patients with deferiprone n 33 and deferasirox n 27 who regulary perform blood transfusion in 2016. The effectiveness is measured by changes in serum ferritin levels and the cost is median of the total cost, summed from the cost of drugs, medical devices, hospitalization, administration, physician, laboratories and blood bags. Based on the results, the effectiveness of deferasirox 1,164 ng mL is greater than deferiprone 692 ng mL and median total cost of deferasirox is more expensive. The final result showed that cost effective ratio of deferasirox Rp 65.816,68 is lower than deferiprone Rp 74.956,60 , but none of both medications is dominant and therefore we could not determine which medication is more cost effective. If deferiprone is selected, it requires extra cost Rp 52.416,64 to increase the effectivity. Policy maker in healthcare facility need to consider if incremental cost of medication is equal to its increased effectiveness."

"As healthcare costs rise in the United States, debate is ongoing over how to obtain better value for dollars spent. In this context, the use of cost-effectiveness analysis (CEA) is more compelling than ever. This book, written by the Second Panel on Cost-Effectiveness in Health and Medicine, reviews key concepts and analytic challenges in CEA. The authors endorse the original Panels concept of a reference case and support its recommendation that analysts take a broad societal perspective; in addition, they recommend a healthcare sector perspective for a second reference case, as well as an important new framework, the Impact Inventory, for detailing costs and effects. The revisions draw on advances in the field and include three new chapters that capture research on decision modeling, methods for evidence synthesis, and ethical considerations. The volume also includes two new worked examples (Appendix A and Appendix B) to illustrate ways to implement the authors recommendations."

"Latar Belakang/Tujuan: Pasien ikterus obstruktif maligna stadium lanjut membutuhkandrainase bilier. Sten metal memiliki efektivitas yang lebih baik, namun klinisi perlumempertimbangkan patensi sten dan keterbatasan sumber daya, mengingat kesintasanpasien yang rendah. Oleh karena itu analisis efektivitas biaya pada kasus ini penting untukdilakukan.Metode: Penelitian ini merupakan studi kohort retrospektif yang dilakukan di rumahsakit tersier terhadap pasien ikterus obstruktif maligna yang menjalani pemasangan stenbilier paliatif pada Januari 2015 sampai Desember 2018. Perbedaan kesintasan 180-haridianalisis dengan uji log-rank. Perbedaan durasi patensi dianalisis dengan uji Mann-Whitney U. Efektivitas didefinisikan sebagai patensi sten, biaya dihitung denganperspektif rumah sakit menggunakan model decision tree dan dinyatakan dalamincremental cost effectiveness ratio.Hasil: Sebanyak 81 laki-laki dan 83 perempuan dengan rentang usia 24 -88 tahun ikutdalam penelitian ini. Kesintasan 180-hari kelompok sten plastik 35,9% (median 76, 95%IK 50-102 hari) dan sten metal 33,3% (median 55, 95% IK 32 -78 hari). Rerata (SB)patensi sten plastik 123 (8) hari dan sten metal 149 (13) hari (p=0,489). Pemasangan stenbilier metal dapat menghemat biaya sebesar Rp. 1.217.750 untuk setiap penambahandurasi patensi 26 hari.Simpulan: Tidak didapatkan perbedaan antara kesintasan dan patensi antara keduakelompok. Pemasangan sten bilier metal sebagai tata laksana paliatif pada pasien ikterusobstruktif maligna lebih cost-effective dibandingkan sten plastik.

---

Background/Aim: Patients with advanced stage of malignant obstructive jaundice oftenrequire biliary drainage. Metal stent is more effective than plastic stent, but we also oughtto consider of stent patency and resources restraint due to poor patient survival. Hence,cost effectiveness analysis in this case was necessary.Methods: We conducted a retrospective cohort of malignant biliary obstruction patientswho underwent palliative biliary stenting between January 2015 to December 2018 at atertiary hospital. We evaluated the difference of 180-day survival using log-rank test andstent patency duration using Mann-Whitney U test. Effectiveness was defined as stentpatency, cost was calculated using hospital perspective following a decision tree modeland reported as incremental cost effectiveness ratio.Results: A total of 81 men and 83 women aged 24-88 years old were enrolled in thisstudy. 180-day survival was 35.9% (median 76, 95% CI 50 -102 days) and 33.3%(median 55, 95% CI 32 -78 days) for plastic and metal stent group respectively. Mean(SD) of stent patency 123 (8) vs 149 (13) days for plastic and metal stent grouprespectively (p=0.489). Metal stent insertion could save IDR 1,217,750 to get additional26 days of stent patency.Conclusion: There were no differences in survival and patency between the two groups.Metal biliary stent is cost effective than plastic stent for palliation in malignant biliaryobstruction."

"Penyakit Paru Obstruktif Kronik (PPOK) adalah penyakit yang ditandai dengan keterbatasan aliran udara yang tidak sepenuhnya reversibel. Kematian akibat PPOK ini menyumbang 6% dari semua kematian secara global. Data prevalensi spesifik untuk PPOK di Indonesia berdasarkan data Riset Kesehatan Dasar (RISKESDAS) tahun 2013 yaitu 3,7 per seribu orang. Penelitian terdahulu di Indonesia menyatakan bahwa terapi salmeterol-flutikason lebih efektif-biaya apabila dibandingkan dengan terapi formoterol-budesonid. Tujuan dari penelitian ini adalah untuk menganalisis efektivitas-biaya yang lebih baik antara terapi terapi salmeterol-flutikason dan terapi formoterol-budesonid pada pasien PPOK rawat jalan di RSUP Persahabatan tahun 2021-2022. Penelitian retrospektif ini merupakan penelitian observasional yang menggunakan desain penelitian cross-sectional dengan menggunakan data rekam medis pasien, yaitu nilai COPD Assesmen Test (CAT), jenis kelamin, usia, dan komorbiditas. Selain itu, digunakan data billing pasien dilihat dari perspektif rumah sakit yang terdiri atas biaya obat, biaya obat lain, biaya laboratorium, biaya jasa tenaga kesehatan, dan total biaya pengobatan. Sampel yang digunakan pada penelitian ini sebanyak 64 sampel, yang terdiri atas 32 sampel terapi salmeterol-flutikason dan 32 sampel terapi formoterol-budesonid. Berdasarkan hasil penelitian, didapatkan nilai inkremental efektivitas antara kedua terapi sebesar 46,9%. Kemudian didapatkan nilai inkremental biaya antara kedua terapi sebesar Rp11.561. Sementara itu, berdasarkan perhitungan didapatkan rasio efektivitas-biaya (REB) untuk terapi salmeterol-flutikason adalah sebesar Rp982.164 /unit efektivitas dan untuk terapi formoterol-budesonid adalah sebesar Rp2.287.610/unit efektivitas. Berdasarkan penelitian, dapat disimpulkan bahwa terapi salmeterol-flutikason lebih memiliki efektivitas-biaya dengan nilai rasio inkremental efektivitas-biaya terapi sebesar Rp247/unit efektivitas.

---

Chronic Obstructive Pulmonary Disease (COPD) is a disease characterized by airflow limitation that is not completely reversible. The total number of deaths from COPD reaches 6% of all deaths globally. Specific prevalence data for COPD in Indonesia are based on Basic Health Research (RISKESDAS) data in 2013 is 3.7 per thousand people. Previous research in Indonesia stated that salmeterol-fluticasone therapy is more cost-effective than formoterol-budesonide therapy. The purpose of this study is to analyze the better cost-effectiveness between salmeterol-fluticasone therapy and formoterol-budesonide therapy in COPD outpatient at Persahabatan General Hospital in 2021-2022. This retrospective study is an observational study with cross-sectional study design using patient medical record data, which consisted of COPD Assessment Test (CAT) scores, gender, age, and comorbidities. In addition, patient billing data is used from a hospital perspective which consisted of drug costs, other drug costs, laboratory fees, health worker service fees, and total medical costs. There were 64 samples used in this study, consisting of 32 samples from salmeterol-fluticasone group and 32 samples from formoterol-budesonide group. Based on results of the study, the increased effectiveness value between the two therapies was 46,9%. Then, the incremental cost value between the two therapies was obtained at IDR11.561. Meanwhile, based on calculations, the average cost-effectiveness ratio (ACER) for salmeterol-fluticasone therapy was IDR 982.164/effectiveness unit and for formoterol-budesonide therapy was IDR 2.287.610/effectiveness unit. Based on the research, it can be concluded that salmeterol-fluticasone therapy is more cost-effective with an incremental cost-effectiveness ratio is Rp247 per unit of effectiveness.

"